Copaxone's effect on MRI-monitored disease in relapsing MS is reproducible and sustained.
All but 6% of the subjects with relapsing remitting MS who were randomly assigned to receive glatiramer acetate or placebo for the 9-month controlled phase of the European/Canadian MRI trial entered an open-label extension with quarterly clinical and MRI evaluations for another 9 months. There was a 54% reduction in the mean number of enhanced lesions for those converted from placebo to glatiramer acetate and an additional 24.6% reduction for those always on glatiramer acetate. Over the entire study the accumulated T2 disease burden was 34.2% less for those always on glatiramer acetate.
Wolinsky
J S
JS
The University of Texas Health Science Center at Houston, 6431 Fannin Street, Houston, TX 77030, USA. Jerry.S.Wolinsky@uth.tmc.edu
Comi
G
G
Filippi
M
M
Ladkani
D
D
Kadosh
S
S
Shifroni
G
G
D018592:Cross-Over Studies; D004311:Double-Blind Method; D000068717:Glatiramer Acetate; D006801:Humans; D008279:Magnetic Resonance Imaging; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000188:drug therapy* / Q000473:pathology; D010455:Peptides / Q000627:therapeutic use*
D010455:Peptides; D000068717:Glatiramer Acetate